Contract Management for Life Sciences (2026)

Life sciences is one of the most contract-intensive and most heavily regulated industries there is. A pharmaceutical, biotech or medical device company signs agreements across research, clinical trials, manufacturing, supply, distribution and commercialisation, each one carrying regulatory, safety and intellectual property weight. The stakes are high: a mishandled clinical trial agreement can delay a study, a weak intellectual property clause can erode years of research value, and a non-compliant arrangement with a healthcare professional can draw regulatory action. This guide sets out the real contract types in life sciences, the pressures that make them hard, the common pain points and what good contract management looks like. It is general information, not legal or regulatory advice; confirm specifics with your own counsel and regulatory team. ## The contract types life sciences companies manage The estate spans the full product lifecycle, from discovery to market: - Clinical trial agreements with sites, hospitals, investigators and contract research organisations, governing how studies are run, paid for and reported.

• Research collaboration and sponsored research agreements with universities and institutions, often with sensitive intellectual property terms.
• Material transfer agreements governing the exchange of biological or chemical materials for research.
• Licensing and intellectual property agreements, including in-licensing and out-licensing of compounds, patents and technology, which can be among the most valuable contracts a company holds.
• Manufacturing and supply agreements, including with contract manufacturing organisations, covering quality, capacity and specifications.
• Quality and technical agreements that sit alongside supply deals and define regulatory and quality responsibilities.
• Distribution and commercialisation agreements for getting products to market in each territory.
• Agreements with healthcare professionals and institutions, such as consulting, advisory board and speaker arrangements, which carry particular compliance sensitivity.
• Clinical and personal data processing terms wherever patient or trial data is handled.
• Confidentiality agreements protecting research and deal information at every stage. The defining feature is that each contract is tied to a regulated activity, so the contract and the compliance obligation are inseparable. ## The regulatory pressures that shape life sciences contracts Few industries carry this weight of regulation, and it reaches straight into the contracts: - Good practice standards. Research, clinical and manufacturing activities are governed by good clinical, laboratory and manufacturing practice standards, and contracts must allocate those responsibilities clearly, often through dedicated quality or technical agreements.
• Clinical trial and medicines regulation. Trial agreements must align with the rules of each regulator and with ethics and consent requirements, and they govern safety reporting and data handling.
• Transparency and anti-bribery rules. Payments and transfers of value to healthcare professionals and institutions are subject to transparency reporting and strict anti-bribery and anti-kickback rules in many markets, so these arrangements have to be structured and documented carefully.
• Data protection. Clinical and patient data brings the GDPR, UK GDPR and similar laws into play, with specific contractual terms required.
• Intellectual property. The value of a life sciences company often sits in its patents and know-how, so licensing, ownership and confidentiality terms are commercially critical and frequently complex.
• Pharmacovigilance and safety. Obligations to collect and report adverse events can flow through many contracts and must be tracked. ## The common pain points Life sciences legal and contracting teams tend to hit the same recurring problems: - Complexity and specialism. Agreements are long, technical and cross-functional, involving legal, regulatory, quality, clinical and commercial teams at once.
• Obligation tracking. Safety reporting, milestone, royalty and quality obligations are buried in contracts and easy to lose.
• Milestone and royalty management. Licensing deals carry payment milestones and royalty terms that have to be tracked precisely over many years.
• Version and audit control. Regulated activities demand a defensible record of every version and approval.
• Slow cross-functional review. Getting legal, regulatory and quality sign-off on complex agreements can be slow, delaying studies and deals.
• Fragmentation. Contracts scattered across functions and systems make it hard to see the full picture for a given programme or partner. ## What good contract management looks like For life sciences, good contract management is built for complexity, compliance and long time horizons: - A single, searchable repository so every agreement, and its obligations and key dates, can be found and audited quickly.
• Standard templates and a controlled clause library for compliance-sensitive terms, kept aligned with current regulation.
• Structured obligation and milestone tracking so safety reporting, royalties, milestones and quality duties are captured and flagged.
• Clear cross-functional workflows so legal, regulatory, quality and commercial teams review the right agreements without becoming bottlenecks.
• Per-clause risk visibility so reviewers can see fast where an agreement departs from policy or carries exposure.
• A defensible audit trail so every version, change and approval is recorded, as regulated activity demands.
• Controlled access so sensitive intellectual property and clinical terms are seen only by those who should see them. The goal is control and defensibility across long, complex, regulated relationships. ## How an AI contract workspace can help Much of this, drafting from tuned templates, flagging risky or non-compliant clauses, tracking milestones, royalties and safety obligations, and keeping a clear, auditable version history, is what a modern AI contract workspace is built to carry. Adira is an AI legal operating system that keeps drafting, per-clause risk review, plain-English clause editing, versioning, compliance tracking and a live activity timeline in one place, tuned to your own organisation and built on frontier AI. It is India-first today with other jurisdictions on its roadmap, so life sciences teams should verify local and sector-specific regulatory depth, and confirm that any tool meets their data protection and validation requirements, before relying on it. You can read more at Adira. The practices above stand on their own. ## Bottom line Life sciences companies manage long, technical contracts across research, trials, manufacturing, licensing and commercialisation, each tied to a regulated activity so that the contract and the compliance obligation are inseparable. Good contract management means a searchable, auditable repository, controlled templates aligned with regulation, structured tracking of obligations, milestones and royalties, clear cross-functional workflows, per-clause risk visibility and a defensible audit trail. Treat contract management as part of regulatory control, not just paperwork, and confirm sector-specific requirements with your own counsel and regulatory team.